Searched for
PEGFILGRASTIM
Drug maker Lupin inks licensing pact with Axantia for PegfilgrastimPegfilgrastim is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients receiving chemotherap...01 Feb, 2022, 01.43 PM IST- Lupin announces USFDA acceptance for a biosimilar applicationThe pegfilgrastim filing is the company's first biosimilar filing in the US and is a milestone in the drug maker's research and innovation ...02 Jun, 2021, 05.32 PM IST
- Reduce Biocon, target price Rs 250: EdelweissThe stock is trading at 32 times FY22E EPS, which factors in the benefit from potential launches, but not the risks involved.18 May, 2020, 11.50 AM IST
- Biocon jumps 4% on launch of drug Fulphila in CanadaBiocon has shared or co-exclusive commercialisation rights with Mylan for the product in the rest of the world.29 Apr, 2020, 03.43 PM IST
- Biocon, Mylan launch cancer drug in CanadaFulphila, co-developed by Biocon Biologics and Mylan, was the first biosimilar pegfilgrastim to be approved in the US and was launched in J...28 Apr, 2020, 09.42 PM IST
- Biocon, Mylan launch cancer drug in AustraliaFulphila, co-developed by Biocon Biologics and Mylan, was the first biosimilar pegfilgrastim to be approved in the US and was launched in J...14 Apr, 2020, 10.30 AM IST
- Latest launches to help Biocon reach billion-dollar biosimilar sales by 2022: Kiran Mazumdar ShawHerceptin is a biosimilar trastuzumab is going to be a major launch for both Biocon & Mylan.03 Dec, 2019, 09.51 AM IST
- Biocon, Mylan get USFDA nod for pegfilgrastim drug substance licenceThis additional approval of its new manufacturing facility for pegfilgrastim in Bengaluru will enable the biotechnology major to enable its...27 Nov, 2019, 05.22 PM IST
- Desi pharma companies top in biosimilars globallyBiosimilars are approved versions of biopharmaceuticals — complex medicines manufactured using live organisms, as against conventional drug...29 Oct, 2018, 10.31 AM IST
- Biocon-Mylan's cancer drug gets USFDA nodFulphila is expected to contribute to Biocon’s revenue in FY19, as well as to its profits through a profitshare arrangement with Mylan.06 Jun, 2018, 11.15 AM IST
- Biocon shares gain on updates on proposed biosimilars Trastuzumab and PegfilgrastimOn the BSE, 1.61 lakh shares were traded on the counter so far in the trade.01 Dec, 2017, 03.58 PM IST
- Biocon rallies over 7% as USFDA issues CRL for proposed biosimilarThis product is a part of the biosimilars portfolio being developed jointly by Biocon and Mylan, the company said in a BSE filing.10 Oct, 2017, 04.05 PM IST
- USFDA issues CRL for proposed biosimilar Pegfilgrastim: BioconThe company said it does not expect the CRL to impact the timing of the launch of biosimilar Pegfilgrastim in the US market.10 Oct, 2017, 02.19 PM IST
- Biocon gets CRL from USFDA for anti-cancer drugThe company, however, said it does not expect this CRL to impact the commercial launch timing of biosimilar Pegfilgrastim in the US.10 Oct, 2017, 11.59 AM IST
- USFDA accepts Mylan's BLA for proposed biosimilar PegfilgrastimThe proposed biosimilar Pegfilgrastim is one of the six biologic products co-developed by Mylan and Biocon for the global marketplace, the ...17 Feb, 2017, 04.12 PM IST
- US FDA accepts Biocon-Mylan biosimilar application for proposed anti-cancer bio-similarBiocon said that the FDA's acceptance for review of this biosimilar is an outcome of the company’s strong R&D and manufacturing capabilitie...16 Feb, 2017, 08.28 PM IST
- EMA accepts marketing application of Biocon, Mylan productMylan and Biocon, who co-developed the proposed biosimilar, received EMA's acceptance of the submission for review, Biocon said in a statem...21 Jul, 2016, 09.36 PM IST
Load More
